SCHEMBL23574144

SCHEMBL23574144

N#CN1CCN2CCN(c3cnc(-c4cccc5[nH]ncc45)cn3)C(=O)C2C1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 3/20 0.44
OTUD7B Q6GQQ9 5/20 0.42
ROCK2 O75116 1/20 0.36
ROCK1 Q13464 1/20 0.36
PRKCA P17252 1/20 0.34
FLT3 P36888 1/20 0.34
GSK3B P49841 1/20 0.34
PRKCQ Q04759 1/20 0.34
CHRNA7 P36544 1/20 0.34
PIK3CD O00329 1/20 0.33
METAP2 P50579 1/20 0.32
PIK3CA P42336 2/20 0.32
MTOR P42345 1/20 0.32
ACVR1 Q04771 1/20 0.32
KDM5B Q9UGL1 1/20 0.32
BRD4 O60885 1/20 0.32
CREBBP Q92793 1/20 0.32
PIK3CG P48736 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30986857 1.00 USP30 (0.44) USP30OTUD7BROCK2ROCK1PRKCA
SCHEMBL23574137 1.00 USP30 (0.44) USP30OTUD7BROCK2ROCK1PRKCA
SCHEMBL30986836 0.88 USP30 (0.49) USP30OTUD7BCHRNA7PIK3CDMETAP2
SCHEMBL23574029 0.88 USP30 (0.49) USP30OTUD7BCHRNA7PIK3CDMETAP2
SCHEMBL30986858 0.88 OTUD7B (0.44) USP30OTUD7BROCK2ROCK1CHRNA7
SCHEMBL23574079 0.88 OTUD7B (0.44) USP30OTUD7BROCK2ROCK1CHRNA7
SCHEMBL23574073 0.88 OTUD7B (0.44) USP30OTUD7BROCK2ROCK1CHRNA7
SCHEMBL23574031 0.88 USP30 (0.49) USP30OTUD7BCHRNA7PIK3CDMETAP2
SCHEMBL23574108 0.86 TYRO3 (0.33) USP30OTUD7BROCK2
SCHEMBL23574102 0.86 TYRO3 (0.33) USP30OTUD7BROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3793997-B1 FUSED BICYCLIC COMPOUNDS USEFUL AS UBIQUITIN-SPECIFIC PEPTIDASE 30 INHIBITORS FORMA THERAPEUTICS INC (US) 2024-03-13 EP claimed
EP-3793997-B1 FUSED BICYCLIC COMPOUNDS USEFUL AS UBIQUITIN-SPECIFIC PEPTIDASE 30 INHIBITORS FORMA THERAPEUTICS INC (US) 2024-03-13 EP disclosed
US-20210198263-A1 FUSED BICYCLIC COMPOUNDS USEFUL AS UBIQUITIN-SPECIFIC PEPTIDASE 30 INHIBITORS FORMA THERAPEUTICS, INC. (US) 2021-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210198263-A1 FUSED BICYCLIC COMPOUNDS USEFUL AS UBIQUITIN-SPECIFIC PEPTIDASE 30 INHIBITORS USP30, UCHL1, ADRM1 USP30 1/4885OTUD7B 593/4885ROCK2 4284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.